The combination of CDK4 and MAPK/ERK pathway inhibitor therapy in Melanoma: defining melanoma cell intrinsic and immune mediated responses

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1100189

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Early-stage melanomas can often be cured with surgery, but more advanced melanomas are harder to treat because standard melanoma treatments do not induce long term disease control. Thus newer types of treatment are required to treat more advanced melanomas. Our proposal will use a drug that stops melanoma cells from growing and in combination with other drugs causes the cells to release factors that activate the immune system to eliminate the tumour.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $824,288.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer cell biology | cancer immunotherapy | cancer therapy | melanoma | signalling pathways

Related Links

ACN 633 798 857